Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MDGL Madrigal Pharmaceuticals, Inc.

已收盘 07-02 16:00:00 EDT

528.10

+13.71

+2.67%

盘后517.00

-11.10-2.10%

19:59 EDT

最高529.73	最低507.60	成交量22.19万
今开512.34	昨收514.39	日振幅4.30%
总市值121.76亿	流通市值58.09亿	总股本2,306万
成交额1.16亿	换手率2.02%	流通股本1,100万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals, Inc.","latestPrice":528.1,"timestamp":1783022400000,"preClose":514.39,"halted":0,"volume":221894,"hourTrading":{"tag":"盘后","latestPrice":517,"preClose":528.1,"latestTime":"19:59 EDT","volume":15372,"amount":8096224.8562,"timestamp":1783036750295,"change":-11.1,"changeRate":-0.021019,"amplitude":0.021019},"delay":0,"changeRate":0.02665292871167798,"floatShares":11000087,"shares":23055522,"eps":-13.421304,"marketStatus":"已收盘","change":13.71,"latestTime":"07-02 16:00:00 EDT","open":512.34,"high":529.73,"low":507.6,"amount":116079179.66917999,"amplitude":0.043022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.421304,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":514.39,"preHourTrading":{"tag":"盘前","latestPrice":517.5,"preClose":514.39,"latestTime":"08:36 EDT","volume":4,"amount":2070,"timestamp":1782995792282,"change":3.11,"changeRate":0.006046,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":517,"preClose":528.1,"latestTime":"19:59 EDT","volume":15372,"amount":8096224.8562,"timestamp":1783036750295,"change":-11.1,"changeRate":-0.021019,"amplitude":0.021019},"volumeRatio":0.276891,"impliedVol":0.5679,"impliedVolPercentile":0.494},"requestUrl":"/m/hq/s/MDGL","defaultTab":"news","newsList":[{"id":"1147300726","title":"Madrigal公布数据：Rezdiffra在MASH患者中降低心血管及肝脏相关风险标志物","url":"https://stock-news.laohu8.com/highlight/detail?id=1147300726","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147300726?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:00","pubTimestamp":1779883246,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals公布的最新研究数据显示，其药物Rezdiffra在治疗代谢功能障碍相关脂肪性肝炎（MASH）患者时，能够有效降低与心血管疾病及肝脏损伤相关的风险标志物水平。这一发现进一步支持了Rezdiffra在改善MASH患者长期健康结局方面的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111379185","title":"异动解读 | Madrigal制药宣布Ervogastat/Resmetirom药物相互作用研究进展，股价盘前大涨7.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111379185","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111379185?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:05","pubTimestamp":1778076344,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.（MDGL）今日盘前股价大涨7.44%，引起了市场的广泛关注。消息面上，公司宣布其针对Ervogastat/Resmetirom的药物相互作用研究正稳步推进，预计将于2026年第四季度正式启动。这项研究旨在评估该联合疗法在临床应用中可能产生的相互作用，为后续开发提供关键数据支持，增强了市场对公司研发进展和未来前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182779005","title":"Madrigal制药公司：Ervogastat/Resmetirom药物相互作用研究按计划将于2026年第四季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1182779005","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182779005?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:03","pubTimestamp":1778065433,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.宣布，其针对Ervogastat/Resmetirom的药物相互作用研究正稳步推进，预计将于2026年第四季度正式启动。这项研究旨在评估该联合疗法在临床应用中可能产生的相互作用，为后续开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164904930","title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计增160.32%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1164904930","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164904930?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:11","pubTimestamp":1777432293,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.将于2026年05月06日发布2026年第一季度财报，市场聚焦收入放量与亏损收窄节奏及商业化质量。主营业务亮点：公司收入结构以“产品”业务为核心，上季度实现营收3.21亿美元，同比增长210.77%。一致预期显示本季度营收为2.96亿美元，同比增160.32%，指向处方数量与可及性继续提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计增160.32%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167627965","title":"异动解读 | 第四季度净亏损超出预期，Madrigal制药盘中大跌8.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167627965","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167627965?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:46","pubTimestamp":1771512383,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc. (MDGL) 今日盘中大跌8.75%，引起了市场的广泛关注。消息面上，公司公布第四季度财报，每股亏损2.57美元，远高于分析师预期的每股亏损40美分，净亏损超出预期，这导致投资者担忧公司盈利能力，从而引发股价下跌。尽管公司第四季度净营收为3.211亿美元，略高于预期的3.125亿美元，且Truist Securities指出收入增长反映了公司的持续进步，有助于增强投资者信心，但亏损扩大仍是市场关注的焦点。截至12月31日，公司拥有现金、现金等价物等约9.886亿美元，财务状况相对稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102468548","title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计大幅增长，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1102468548","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102468548?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:40","pubTimestamp":1770864055,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.将于2026年02月19日发布最新季度财报，市场关注resmetirom商业化早期放量与利润端承压的权衡，以及公司对全年运营节奏与费用率的更新指引。基于一致预期，本季度Madrigal Pharmaceuticals, Inc.预计营收为3.12亿美元，同比增速为217.06%；预计调整后每股收益为-0.59美元，同比增速为86.18%；预计息税前利润为-0.82千万美元，同比增速为91.62%。上季度Madrigal Pharmaceuticals, Inc.营收2.87亿美元；毛利率93.69%；归属母公司净利润为-1.14亿美元，净利率为-39.75%；调整后每股收益为-4.96美元，同比变动为-0.81%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计大幅增长，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100910072","title":"瑞博生物与瑞博制药宣布与Madrigal就靶向MASH的新型siRNA疗法达成独家全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1100910072","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100910072?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:26","pubTimestamp":1770809176,"startTime":"0","endTime":"0","summary":"瑞博生物（股票代码：06938）与瑞博制药（RIBOLIFE-B）今日宣布，已与Madrigal Pharmaceuticals（股票代码：MDGL）就针对代谢功能障碍相关脂肪性肝炎（MASH）的新型小干扰RNA（siRNA）疗法签署独家全球许可协议。\n根据协议条款，Madrigal将获得上述siRNA疗法在全球范围内的独家开发及商业化权利。此次合作旨在加速该创新疗法的研发进程，为MASH患者提供潜在的新型治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","06938","BK4588","BK4585","MDGL","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610024939","title":"Madrigal制药公司授权六个临床前siRNA项目以扩展NASH管线Madrigal Pharmaceuticals Licenses Six Preclinical siRNA Programs to Expand NASH Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2610024939","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610024939?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:13","pubTimestamp":1770808380,"startTime":"0","endTime":"0","summary":"by GOAI由GOAI生成Share To分享到Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement to expand its MASH  pipeline. The agreement includes six preclinical siRNA  programs, which aim to address various aspects of liver disease and metabolic disorders.Madrigal Pharmaceuticals 已达成一项独家全球许可协议，以扩展其 MASH产品线。该协议包括六个临床前的 siRNA项目，旨在解决肝脏疾病和代谢紊乱的各个方面。The licensing deal grants Madrigal access to these six siRNA programs, which are currently in the preclinical stage. These programs focus on utilizing RNA interference technology to target specific pathways associated with liver diseases and metabolic dysfunctions. The company plans to integrate these programs into its existing pipeline for further development and potential clinical trials.该许可协议授予麦德rigal公司访问这六个siRNA项目，这些项目目前处于临床前阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191520a6eec729&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211191520a6eec729&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148640471","title":"瑞博生物-B达成6项代谢功能障碍相关脂肪性肝炎临床前siRNA项目授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1148640471","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148640471?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:05","pubTimestamp":1770804310,"startTime":"0","endTime":"0","summary":"苏州瑞博生命科学（瑞博生物-B）近日宣布，已就6项针对代谢功能障碍相关脂肪性肝炎（MASH）治疗的临床前阶段小干扰RNA（siRNA）研发项目达成授权许可协议。该交易标志着公司在核酸药物研发领域，特别是在代谢性疾病治疗方向的战略布局取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","06938","MDGL","BK4585","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198191065","title":"Madrigal 签署独家全球许可协议，引进六项临床前 siRNA 项目，拓展其 MASH 产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1198191065","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198191065?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:00","pubTimestamp":1770804013,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc. 宣布达成一项独家全球许可协议，引入六个处于临床前阶段的 siRNA（小干扰RNA）项目，此举旨在显著扩展其针对代谢功能障碍相关脂肪性肝炎（MASH）的研发管线。该协议进一步巩固了 Madrigal 在 MASH 治疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517118936","title":"Madrigal Pharmaceuticals, Inc.盘中异动 临近收盘急速跳水5.01%报329.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517118936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517118936?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:58","pubTimestamp":1741294732,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日04时58分，Madrigal Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.01%。截至发稿，该股报329.89美元/股，成交量23.1556万股，换手率1.05%，振幅5.68%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.08%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc 是一家生物制药公司，专注于提供代谢功能障碍相关脂肪性肝炎  的新型疗法，这是一种严重的肝病，具有高度未满足的医疗需求，可能导致肝硬化、肝功能衰竭和过早死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307045853a262ecd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307045853a262ecd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517946676","title":"Madrigal Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517946676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517946676?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:45","pubTimestamp":1741189531,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时45分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.02%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.38%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc 是一家生物制药公司，专注于提供代谢功能障碍相关脂肪性肝炎  的新型疗法，这是一种严重的肝病，具有高度未满足的医疗需求，可能导致肝硬化、肝功能衰竭和过早死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305234531a260dd65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305234531a260dd65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516603054","title":"Madrigal Pharmaceuticals, Inc.跌4.30% 股价跌破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2516603054","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516603054?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:18","pubTimestamp":1741101533,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时18分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价急速跳水4.30%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nutriband Inc C/Wts 涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1171.70%、1133.53%、680.05%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Celularity Inc C/Wts 16/07/2026 、Protagenic Therapeutics Inc C/Wts 29/04/2026 ，振幅分别为66.03%、66.02%、64.44%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231853abe7fdc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231853abe7fdc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634270","title":"Madrigal Pharmaceuticals, Inc.盘中异动 急速下挫5.35%报323.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634270?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:48","pubTimestamp":1741013289,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时48分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.35%。截至发稿，该股报323.02美元/股，成交量3.3061万股，换手率0.15%，振幅3.05%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Geovax Labs, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为368.92%、109.98%、69.27%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025，振幅分别为140.46%、68.30%、24.83%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224810989a1449&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224810989a1449&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516548069","title":"Madrigal Pharmaceuticals, Inc.2024财年实现净利润-4.66亿美元，同比减少24.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548069","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516548069?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931237,"startTime":"0","endTime":"0","summary":"3月3日，Madrigal Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-4.66亿美元，同比减少24.60%；其中营业收入为1.80亿美元，每股基本收益为-21.90美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.总负债2.88亿美元，其中短期债务983000.00美元，资产负债比为3.62，流动比率为6.12。机构评级：截至2025年3月3日，当前有16家机构对Madrigal Pharmaceuticals, Inc.目标价做出预测，其中目标均价为411.31美元，其中最低目标价为239.00美元，最高目标价为544.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000057abe4aca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000057abe4aca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514332004","title":"Madrigal Pharmaceuticals, Inc.盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514332004","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514332004?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:43","pubTimestamp":1740688985,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时43分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.18%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。其相关个股中，Pepgen Inc.、Ibio, Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1943.02%、410.26%、197.12%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228044306abdfbfc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228044306abdfbfc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514394334","title":"花旗：维持Madrigal Pharmaceuticals(MDGL.US)评级，由买入调整至买入评级, 目标价由378.00美元调整至469.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514394334","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514394334?lang=zh_cn&edition=full","pubTime":"2025-02-28 03:31","pubTimestamp":1740684698,"startTime":"0","endTime":"0","summary":"花旗：维持Madrigal Pharmaceuticals(MDGL.US)评级，由买入调整至买入评级, 目标价由378.00美元调整至469.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28033148442056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102872556","title":"异动解读 | MDGL公布罕见好于预期财报 股价盘中大涨8.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102872556","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102872556?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:40","pubTimestamp":1740580847,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals今日盘中大涨8.24%,引发了市场的广泛关注。这主要源于公司公布了一组罕见的好于市场预期的2024年第四季度财报。与上年同期相比,MDGL的营收和利润均出现了明显改善。出色的财报传递出MDGL经营向好、业务状况改善的利好信号,这不仅提振了投资者对公司长期增长前景的信心,也证明公司在生物医药行业的发展步伐正在加快。MDGL股价盘中大涨8.24%,正是充分体现了投资者对公司前景的看涨预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514186856","title":"Madrigal Pharmaceuticals, Inc.盘中异动 早盘急速拉升8.80%报336.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514186856","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514186856?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:32","pubTimestamp":1740580332,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价急速拉升8.80%。截至发稿，该股报336.74美元/股，成交量9912股，换手率0.05%，振幅1.54%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2798.65%、116.09%、90.30%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为29.66%、16.86%、14.35%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223212a254f696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223212a254f696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179187165","title":"异动解读 | 马德里加尔制药公司发布2024年第四季度业绩佳绩，盘前涨幅6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179187165","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179187165?lang=zh_cn&edition=full","pubTime":"2025-02-26 21:50","pubTimestamp":1740577857,"startTime":"0","endTime":"0","summary":"今日盘前，马德里加尔制药公司(MDGL)股价出现大涨6.63%的行情，引起了市场的广泛关注。\n\n导致该股价大涨的主要原因是，公司在昨日发布的2024年第四季度财报数据优于市场预期。具体来看，马德里加尔制药公司在本季度实现营收1.033亿美元，高于预期的9125万美元；此外，每股盈利亏损2.71美元，优于预期亏损4.12美元。与去年同期相比，公司的营收和净利润均出现了大幅改善。\n\n得益于这组出色的财报数据，投资者对马德里加尔制药公司未来的增长前景更加看好，从而推动了今日盘前股价的大涨。公司的优异表现将为其在生物医药行业的持续发展注入新的动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.0689},{"period":"3month","weight":-0.0594},{"period":"6month","weight":-0.1338},{"period":"1year","weight":0.7137},{"period":"ytd","weight":-0.1167}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Madrigal Pharmaceuticals, Inc.于2000年3月成立并在2001年7月开始运营。该公司是一家生物制药公司，专注于为代谢功能障碍相关脂肪性肝炎提供新的治疗方法。脂肪性肝炎是一种严重的肝病，其医疗需求高度未得到满足，可导致肝硬化、肝衰竭、癌症、肝移植需求和过早死亡。该公司的药物Rezifra是一种每日一次的口服肝脏导向甲状腺激素受体β激动剂，旨在针对MASH的关键潜在原因。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006598},{"month":5,"riseRate":0.3,"avgChangeRate":0.113604},{"month":6,"riseRate":0.7,"avgChangeRate":0.037265},{"month":7,"riseRate":0.1,"avgChangeRate":-0.075247},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals, Inc.","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Madrigal Pharmaceuticals, Inc.,MDGL,Madrigal Pharmaceuticals, Inc.股票,Madrigal Pharmaceuticals, Inc.股票老虎,Madrigal Pharmaceuticals, Inc.股票老虎国际,Madrigal Pharmaceuticals, Inc.行情,Madrigal Pharmaceuticals, Inc.股票行情,Madrigal Pharmaceuticals, Inc.股价,Madrigal Pharmaceuticals, Inc.股市,Madrigal Pharmaceuticals, Inc.股票价格,Madrigal Pharmaceuticals, Inc.股票交易,Madrigal Pharmaceuticals, Inc.股票购买,Madrigal Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}